Pharmala Biotech Holdings (XCNQ:MDMA) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XCNQ:MDMA Pharmala Biotech Holdings Inc XCNQ:MDMA
38 GF Score
Price C$0.25
GF Value C$0.25
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Pharmala Biotech Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XCNQ:MDMA vs VRTX, REGN, RVMD: Short Interest Comparison

For the Biotechnology subindustry, Pharmala Biotech Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Short Interest falls into.


XCNQ:MDMA
38GF Score
Pharmala Biotech Holdings Inc XCNQ:MDMA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharmala Biotech Holdings (XCNQ:MDMA) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of C$0.25 is trading 0% below its estimated GF Value™ of C$0.25. GuruFocus considers Pharmala Biotech Holdings to be Fairly Valued.

Key valuation signals for XCNQ:MDMA:

  • Short Interest:
  • GF Value™: C$0.25 vs. price of C$0.25 (0% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the XCNQ:MDMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDXXF:USA
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
38GF Score

Get the complete analysis for XCNQ:MDMA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.25
Price
C$0.25
GF Value